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evident on the Satisfaction domain and the Psychological
Reward domain.
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OBJECTIVES: The 10-item version of the 32-item Questionnaire
of Smoking Urges (the QSU-brief) provides a multidimensional
measure of craving to smoke. Previous research from a factor
analysis of the QSU-brief supported a two-factor structure with
Factor 1 measuring “a strong desire and intention to smoke 
with smoking perceived as rewarding” and Factor 2 measuring
“demonstrating anticipation of relief from negative affect and an
urgent desire to smoke”. We conducted an independent investi-
gation of the QSU-brief to assess the validity and reliability of
the proposed two-factor structure. METHODS: Data came from
a seven-week Phase II clinical trial (n = 626) of varenicline devel-
oped for smoking cessation. The two pre-speciﬁed domains from
previous research were Factor 1 (5 items) and Factor 2 (3 items).
Factor analyses and internal consistency reliability analyses
(Cronbach’s alpha) were conducted during occasions when
varying levels of craving intensity might be expected (baseline,
Week 2, and Week 4). RESULTS: The hypothesized multidi-
mensional framework of the QSU-brief was supported by con-
ﬁrmatory factor analysis at each of the three occasions (baseline,
Week 2, Week 4). Comparative ﬁt indexes (CFI) and non-normed
ﬁt indexes (NNFI) exceeded 0.90 (CFI = 0.97, 0.95, 0.96; NNFI
= 0.96, 0.93, 0.95). Values of Cronbach’s alpha exceeded 0.75
on Factor 1 (0.90, 0.89, 0.90) and Factor 2 (0.76, 0.78, 0.85),
as well as on the Total Score of 10 items (0.92, 0.93, 0.93).
CONCLUSION: The validity and reliability of the postulated
two dimensional structure of self-reported craving as measured
by the QSU-brief is conﬁrmed.
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OBJECTIVES: To assess the cost-effectiveness of 18-month
treatment with clopidogrel versus aspirin in high-risk patients
with a recent history of Ischemic Stroke (IS) or Transient
Ischemic Attack (TIA) in four European countries: Belgium,
France, Switzerland, and UK. METHODS: We developed a
Markov model based on patients with IS or TIA in the previous
90 days (median 15 days) who were treated with clopidogrel in
the MATCH trial and followed prospectively for the occurrence
of recurrent IS or TIA, myocardial infarction (MI), other car-
diovascular death, life threatening bleeding, or major bleeding.
The event rates for IS and TIA patients treated with aspirin were
derived from a Cochrane review comparing clopidogrel and
aspirin by using a relative risk increase (RRI) of 1.11 for serious
vascular events (all strokes, MI, cardiovascular deaths). For
major bleedings with aspirin vs. clopidogrel, we used a RRI of
1.12 (CAPRIE trial). Death rates for other causes were country
speciﬁc and adjusted for this population. Lifetime perspective
was chosen and discount rates were applied according to the
local guidelines. RESULTS: Eighteen-month treatment with
clopidogrel compared to aspirin was associated with a gain in
quality adjusted life years (QALY) ranging from 31 years/1000
patients in the UK to 36 years/1000 patients in Belgium. 
The incremental cost per patient varied from 487€ in UK to 
724€ in Belgium and the cost per QALY was 20,111€ in 
Belgium, 18,882€ in France, 15,620€ in Switzerland, and
15,713€ in UK. Sensitivity analyses showed that all results were
robust under various assumptions. CONCLUSION: Consistent
results are found across the four countries with incremental cost-
effectiveness ratio below the acceptable thresholds, demonstrat-
ing that clopidogrel compared to aspirin is always cost-effective
in the studied population.
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EVALUATING THE POTENTIAL COST-EFFECTIVENESS OF
FUTURE ANTICOAGULANT DRUGS VS.WARFARIN IN THE
PREVENTION OF STROKE AND MAJOR BLEEDS IN ATRIAL
FIBRILLATION PATIENTS
Arant T1, Sullivan P2
1University of Adelaide School of Medicine, Adelaide, S.A, Australia;
2University of Colorado, Denver, CO, USA
OBJECTIVES: To determine the attributes of future anti-
coagulation drug candidates necessary to demonstrate cost-
effectiveness versus traditional warfarin therapy in the 
prevention of stroke and major bleeds in Atrial Fibrillation
(“AF”) patients. METHODS: A decision-analytic model was
constructed to simulate the population of individuals using war-
farin therapy versus a proxy (future) anticoagulation drug in
patients with AF. Exposure period, dosage and base case proba-
bilities for major bleeds and hepatotoxity were based on the war-
farin raw data from the Sportif III and V trials. The beneﬁts
associated with using warfarin therapy versus a proxy future
drug in patients with AF were quantiﬁed using the quality-
adjusted life year (QALY) framework. Univariate and multivari-
ate probabilistic sensitivity analyses using Bayesian second-order
Monte Carlo simulation were conducted. Hepatoxicity-related
risks were estimated pursuant to FDA’s usage of Hy’s Law.
RESULTS: The results of the base-case analysis demonstrate that
treatment with warfarin results in an expected cost $307 less
than treatment with a proxy future anticoagulant drug ($882.70
compared with $1189.90, respectively). The proxy drug proﬁle
is not cost effective (incremental cost-effectiveness ratio of
$960,000 per QALY) compared to warfarin. Warfarin dominates
treatment vs. the proxy drug with 84% probability. CONCLU-
SIONS: Recent new anticoagulant candidate drugs have not been
shown to be cost-effective compared to warfarin. To achieve
market acceptance, future anticoagulant drugs must be able to
demonstrate competitive cost, non-inferiority of stroke/major
bleed prevention and a superior safety proﬁle including reduc-
tion of hepatotoxicity risk.
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OBJECTIVE: Health-related utility is poorly characterised in
stroke patients with limb spasticity. The purpose of this study
was to evaluate health utility in stroke patients with and without
upper and lower limb spasticity. METHODS: Data were
abstracted from the Health Outcomes Data Repository
(HODaR) describing treatment patterns, outcomes and quality
of life following a modiﬁed survey describing 151 patients 
who had experienced a stroke in the last two years. Data were
available describing demographics, the EQ5D and the pres-
ence/absence of self reported limb spasticity. These data were
then linked to routine hospital inpatient data. RESULTS: The
mean age was 72.4 years (56% males). One quarter (26.5%) of
respondents reported no limb spasticity. Of the remainder,
13.9% reported upper limb spasticity only, 11.2% lower limb
spasticity only, and 27.2% a combination of both. Overall, the
mean EQ5Dindex for these patients was 0.55, although patients
reporting no limb spasticity had a higher EQ5Dindex (0.73) com-
pared to those reporting lower limb spasticity (0.36; D = 0.37).
There was a notable difference in utility between those with
upper and lower limb spasticity where patients reporting lower
limb spasticity had lower health utility (0.36 vs. 0.62 respec-
tively; D = 0.26). A similar pattern existed in their duration of
hospital stay with patients experiencing upper and lower limb
spasticity having a mean length of stay of 42.7 days compared
to 29.1 days (lower limb spasticity only) and 20.5 days (upper
limb spasticity only). Patients reporting no limb spasticity had a
mean length of stay of 10.2 days. CONCLUSIONS: The mean
utility estimates obtained from this study show stroke patients
experienced a substantial decrease in quality of life and a further
decrease was recorded in those patients reporting upper and/or
lower limb spasticity. Limb spasticity was also associated with a
substantial increase in hospital length of stay.
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OBJECTIVES: Anticoagulation with warfarin for stroke pre-
vention requires careful management to avoid hemorrhage or
thrombosis. We evaluated the frequency of international nor-
malized ratio (INR) testing in two high-risk Medicare popula-
tions who are likely to receive adjusted-dose warfarin: 1) patients
diagnosed with atrial ﬁbrillation (AF); and 2) patients with a
mechanical heart valve (MHV). METHODS: We analyzed the
2001 Physician Supplier Procedure Summary Master Files
(PSPSMF) database, a 5% sample of procedure-speciﬁc claims
for all physician/supplier services rendered to Medicare beneﬁ-
ciaries. We identiﬁed patients with AF and MHV based on 
any-listed ICD-9-CM diagnosis code of 427.31 and V43.3,
respectively. For each cohort, we searched for claims billed 
under Current Procedural Terminology (CPT) code 85610—
prothrombin testing. We compared prevalence and frequency of
INR testing for each cohort to expected standards of care.
RESULTS: We identiﬁed 141,757 patients with AF and 10,055
patients with MHV, which would yield projected national esti-
mates of 2.8 million and 200,000 patients, respectively. Sixty
percent of AF patients and 43% of MHV patients did not have
a single INR claim. Of AF patients who had at least one INR
test claim, 41% were tested less than 6 times per year, and 59%
were tested 10 or fewer times per year. For MHV patients, 31%
were tested less than 6 times per year, and 47% were tested 10
or fewer times per year. CONCLUSIONS: Medicare claims his-
tories reveal that clinical practice patterns may not adhere to
accepted standards of care for the prevention of stroke in AF and
MHV. Third-party payment policies, provider behavior, lack of
patient awareness, and other factors may contribute to poor
compliance and possible adverse events. Additional studies are
needed to determine the cause of under-compliance in managing
patients at risk for stroke and how Medicare policies may affect
prescribing decisions and patient outcomes.
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OBJECTIVE: To evaluate continuity of care (CoC) and social
capital in stroke patients under rehabilitation in the Mexican
Institute of Social Security (IMSS). METHODS: Cross sectional
study in three IMSS hospitals in Mexico City. Inclusion criteria
were: stroke adult patients surviving a ﬁrst ischaemic event,
consent to participate in the study and capable to answer ques-
tions in an interview. No instruments to measure CoC and social
capital in stroke patients were identiﬁed in our previous litera-
ture review. Three instruments to measure CoC were used:
Mexican one (Constantino), from United States (Chao) and from
Canada (Salmoni). The ﬁrst one is being validated and the other
two have been used and validated in general practice and chronic
patients discharged from hospital to community, respectively.
RESULTS: Forty stroke patients were interviewed, mean age was
68 years, education of 7 years and 87.5% had some chronic
illness (hypertension 58.3%). Sixty seven percent informed that
they were receiving formal rehabilitation and that in 88.2% it
met their needs and expectancies. The Mexican instrument (scale
from 1 to10) found a mean score for patient perception of CoC
of 7.1 and from carer/relative 8.1. Patients said they trusted their
doctor in 83.3% (Chao instrument). Opinion in relation to 
hospital care quality was: poor in 16.8%, regular in 12.5% 
and good/very good in 50% (Salmoni instrument). About social
capital: 91.6% trusted public institutions in their community and
in people living in the neighbourhood in 54.2%. Patients
received help to attend medical facilities in 4.2% from the neigh-
bour, 4.2% from a friend; patients helped the neighbour in
16.7% and a friend in 54.2%. CONCLUSIONS: Most of stroke
patients interviewed were satisﬁed with the quality of rehabili-
tation provided by the IMSS. CoC score from patient and carer
was acceptable and similar. Social capital level was also good.
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OBJECTIVES: This study assesses predictors of stroke recur-
rence in a Medicaid population, speciﬁcally examining persis-
tence on clopidogrel, warfarin and aspirin drug therapy.
METHODS: Medical and pharmacy claims for patients with a
diagnosis of stroke (ICD-9 Codes 430–438) were obtained from
Medicaid for the period of January 1, 2001–December 31, 2003.
Only patients with at least one month of follow up were
included. In order to obtain an incident cohort, patients who had
a stroke diagnosis between January 1, 2001–June 30, 2001 were
